Kevin Espinola counsels a broad range of public and private companies in mergers and acquisitions, corporate governance, general corporate counseling, and corporate finance matters.

Kevin has worked on a wide variety of acquisitions and dispositions, including a broad range of public company mergers, hostile takeovers, leveraged buyouts, asset divestitures, and asset acquisitions. In these transactions, he has represented a full range of parties, including buyers, sellers, special committees, and financial advisors, including Advantage Sales & Marketing, Amgen, BioMarin, Celgene, CIMA Labs, Deutsche Bank, First Consulting Group, Harrah's Entertainment, ICOS, K-V Pharmaceutical, Medicis Pharmaceutical, Piper Jaffray, Varco International, SAP, and Watson Pharmaceuticals.

Kevin's corporate counseling experience spans a broad range of industries, including biotechnology, pharmaceuticals, medical device, semiconductor, internet, technology, nutritional supplements, and real estate. Kevin also has represented issuers and underwriters in private and public offerings.

He has presented on several topics, including mergers and acquisitions, corporate governance, and SEC compliance.